{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:36:04Z","timestamp":1792427764652,"version":"4.5.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s40266-016-0397-7","type":"journal-article","created":{"date-parts":[[2016,9,9]],"date-time":"2016-09-09T02:38:44Z","timestamp":1473388724000},"page":"619-628","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Targeted Therapy for Older Patients with Uncontrolled Severe Asthma: Current and Future Prospects"],"prefix":"10.1007","volume":"33","author":[{"given":"E. W.","family":"de Roos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. C. C. M.","family":"in \u2019t Veen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.-J.","family":"Braunstahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Lahousse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. G. O.","family":"Brusselle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,9]]},"reference":[{"key":"397_CR1","doi-asserted-by":"crossref","unstructured":"Braman SS. The global burden of asthma. Chest J. 2006;130(1_suppl):4S\u201312S.","DOI":"10.1378\/chest.130.1_suppl.4S"},{"issue":"3 Suppl","key":"397_CR2","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jaci.2011.06.048","volume":"128","author":"NA Hanania","year":"2011","unstructured":"Hanania NA, King MJ, Braman SS, Saltoun C, Wise RA, Enright P, et al. Asthma in the elderly: current understanding and future research needs\u2013a report of a National Institute on Aging (NIA) workshop. J Allergy Clin Immunol. 2011;128(3 Suppl):S4\u201324.","journal-title":"J Allergy Clin Immunol."},{"issue":"1","key":"397_CR3","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.amjmed.2008.09.022","volume":"122","author":"E Stupka","year":"2009","unstructured":"Stupka E, deShazo R. Asthma in seniors: part 1. Evidence for underdiagnosis, undertreatment, and increasing morbidity and mortality. Am J Med. 2009;122(1):6\u201311.","journal-title":"Am J Med"},{"issue":"6","key":"397_CR4","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3109\/02770903.2012.684252","volume":"49","author":"E Oraka","year":"2012","unstructured":"Oraka E, Kim HJ, King ME, Callahan DB. Asthma prevalence among US elderly by age groups: age still matters. J Asthma. 2012;49(6):593\u20139.","journal-title":"J Asthma"},{"key":"397_CR5","first-page":"1","volume":"239","author":"LJ Akinbami","year":"2016","unstructured":"Akinbami LJ, Fryar CD. Current asthma prevalence by weight status among adults: United States, 2001\u20132014. NCHS Data Brief. 2016;239:1\u20138.","journal-title":"NCHS Data Brief."},{"key":"397_CR6","doi-asserted-by":"crossref","unstructured":"Gibson GJ, Loddenkemper R, Sibille Y, Lundback B. The European lung white book: respiratory health and disease in Europe. European Respiratory Society; 2013.","DOI":"10.1183\/09031936.00105513"},{"issue":"18","key":"397_CR7","doi-asserted-by":"crossref","first-page":"25010","DOI":"10.18632\/oncotarget.7075","volume":"7","author":"L Zuo","year":"2016","unstructured":"Zuo L, Pannell BK, Liu Z. Characterization and redox mechanism of asthma in the elderly. Oncotarget. 2016;7(18):25010\u201321.","journal-title":"Oncotarget."},{"issue":"3","key":"397_CR8","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/s1081-1206(10)60907-6","volume":"96","author":"RG Slavin","year":"2006","unstructured":"Slavin RG, Haselkorn T, Lee JH, Zheng B, Deniz Y, Wenzel SE. Asthma in older adults: observations from the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) study. Ann Allergy Asthma Immunol. 2006;96(3):406\u201314. doi: 10.1016\/s1081-1206(10)60907-6 .","journal-title":"Ann Allergy Asthma Immunol"},{"key":"397_CR9","first-page":"A4174","volume":"191","author":"M Forshag","year":"2015","unstructured":"Forshag M, Dalal AA, Ortega H, Yancey S, Gunsoy NB, Canonica G. Healthcare resource use associated with exacerbations in patients with severe eosinophilic asthma. Am J Respir Crit Care Med. 2015;191:A4174.","journal-title":"Am J Respir Crit Care Med"},{"issue":"13","key":"397_CR10","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","volume":"371","author":"EH Bel","year":"2014","unstructured":"Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. New Engl J Med. 2014;371(13):1189\u201397. doi: 10.1056\/NEJMoa1403291 .","journal-title":"New Engl J Med."},{"issue":"4","key":"397_CR11","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jaci.2014.08.042","volume":"135","author":"PP Hekking","year":"2015","unstructured":"Hekking PP, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015;135(4):896\u2013902.","journal-title":"J Allergy Clin Immunol."},{"key":"397_CR12","unstructured":"Global Initiative for Asthma. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2016. http:\/\/www.ginasthma.org . Accessed 24 Apr 2016."},{"issue":"8","key":"397_CR13","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1164\/rccm.200401-033OC","volume":"170","author":"ED Bateman","year":"2004","unstructured":"Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJH, Pauwels RA, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med. 2004;170(8):836\u201344.","journal-title":"Am J Respir Crit Care Med"},{"key":"397_CR14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2466-6-13","volume":"6","author":"MR Partridge","year":"2006","unstructured":"Partridge MR, van der Molen T, Myrseth SE, Busse WW. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med. 2006;6:13.","journal-title":"BMC Pulm Med."},{"issue":"1","key":"397_CR15","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/ni.3049","volume":"16","author":"BN Lambrecht","year":"2015","unstructured":"Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol. 2015;16(1):45\u201356.","journal-title":"Nat Immunol"},{"issue":"2","key":"397_CR16","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/joim.12382","volume":"279","author":"KF Chung","year":"2016","unstructured":"Chung KF. Asthma phenotyping: a necessity for improved therapeutic precision and new targeted therapies. J Intern Med. 2016;279(2):192\u2013204.","journal-title":"J Intern Med"},{"issue":"10","key":"397_CR17","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1136\/thx.2010.153643","volume":"66","author":"EH Bel","year":"2011","unstructured":"Bel EH, Sousa A, Fleming L, Bush A, Chung KF, Versnel J, et al. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). Thorax. 2011;66(10):910\u20137.","journal-title":"Thorax"},{"issue":"5","key":"397_CR18","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1398-9995.2004.00526.x","volume":"59","author":"M Masoli","year":"2004","unstructured":"Masoli M, Fabian D, Holt S, Beasley R, Global Initiative for Asthma P. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004;59(5):469\u201378.","journal-title":"Allergy"},{"issue":"5","key":"397_CR19","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1183\/09031936.00120714","volume":"44","author":"KF Chung","year":"2014","unstructured":"Chung KF, Wenzel S. International European Respiratory Society\/American Thoracic Society guidelines on severe asthma. Eur Respir J. 2014;44(5):1378\u20139.","journal-title":"Eur Respir J"},{"issue":"5","key":"397_CR20","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1111\/j.1532-5415.2009.02216.x","volume":"57","author":"SH Chotirmall","year":"2009","unstructured":"Chotirmall SH, Watts M, Branagan P, Donegan CF, Moore A, McElvaney NG. Diagnosis and management of asthma in older adults: progress in geriatrics. J Am Geriatr Soc. 2009;57(5):901\u20139. doi: 10.1111\/j.1532-5415.2009.02216.x .","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"397_CR21","doi-asserted-by":"publisher","first-page":"427","DOI":"10.2500\/aap.2013.34.3687","volume":"35","author":"J Madeo","year":"2013","unstructured":"Madeo J, Li Z, Frieri M. Asthma in the geriatric population. Allergy Asthma Proc. 2013;35(5):427\u201333. doi: 10.2500\/aap.2013.34.3687 .","journal-title":"Allergy Asthma Proc."},{"issue":"5","key":"397_CR22","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.amjmed.2013.12.013","volume":"127","author":"M Al-Alawi","year":"2014","unstructured":"Al-Alawi M, Hassan T, Chotirmall SH. Advances in the diagnosis and management of asthma in older adults. Am J Med. 2014;127(5):370\u20138. doi: 10.1016\/j.amjmed.2013.12.013 .","journal-title":"Am J Med"},{"issue":"5","key":"397_CR23","doi-asserted-by":"publisher","first-page":"431","DOI":"10.4168\/aair.2015.7.5.431","volume":"7","author":"WJ Song","year":"2015","unstructured":"Song WJ, Cho SH. Challenges in the management of asthma in the elderly. Allergy Asthma Immunol Res. 2015;7(5):431\u20139. doi: 10.4168\/aair.2015.7.5.431 .","journal-title":"Allergy Asthma Immunol Res."},{"key":"397_CR24","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2147\/cia.s33609","volume":"8","author":"AS Melani","year":"2013","unstructured":"Melani AS. Management of asthma in the elderly patient. Clin Interv Aging. 2013;8:913\u201322. doi: 10.2147\/cia.s33609 .","journal-title":"Clin Interv Aging."},{"issue":"3","key":"397_CR25","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1177\/1753465816632638","volume":"10","author":"NC Thomson","year":"2016","unstructured":"Thomson NC. Novel approaches to the management of noneosinophilic asthma. Ther Adv Respir Dis. 2016;10(3):211\u201334. doi: 10.1177\/1753465816632638 .","journal-title":"Ther Adv Respir Dis."},{"issue":"2","key":"397_CR26","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1586\/17476348.2016.1133304","volume":"10","author":"NC Thomson","year":"2016","unstructured":"Thomson NC. Addressing corticosteroid insensitivity in adults with asthma. Expert Rev Respir Med. 2016;10(2):137\u201356. doi: 10.1586\/17476348.2016.1133304 .","journal-title":"Expert Rev Respir Med."},{"issue":"2","key":"397_CR27","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1164\/rccm.200409-1181PP","volume":"172","author":"S Wenzel","year":"2005","unstructured":"Wenzel S. Severe asthma in adults. Am J Respir Crit Care Med. 2005;172(2):149\u201360. doi: 10.1164\/rccm.200409-1181PP .","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"397_CR28","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1038\/nm.3300","volume":"19","author":"GG Brusselle","year":"2013","unstructured":"Brusselle GG, Maes T, Bracke KR. Eosinophils in the spotlight: eosinophilic airway inflammation in nonallergic asthma. Nat Med. 2013;19(8):977\u20139. doi: 10.1038\/nm.3300 .","journal-title":"Nat Med"},{"key":"397_CR29","first-page":"A3861","volume":"187","author":"HG Ortega","year":"2013","unstructured":"Ortega HG, Chupp G, Bardin P, Bourdin A, Hartley B, Humbert M. The role of mepolizumab in atopic and non-atopic patients with refractory eosinophilic asthma. Am J Respir Crit Care Med. 2013;187:A3861.","journal-title":"Am J Respir Crit Care Med"},{"key":"397_CR30","doi-asserted-by":"publisher","first-page":"692546","DOI":"10.1155\/2015\/692546","volume":"2015","author":"MA Murray","year":"2015","unstructured":"Murray MA, Chotirmall SH. The impact of immunosenescence on pulmonary disease. Mediat Inflamm. 2015;2015:692546. doi: 10.1155\/2015\/692546 .","journal-title":"Mediat Inflamm"},{"issue":"5","key":"397_CR31","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.rmed.2010.12.014","volume":"105","author":"N Scichilone","year":"2011","unstructured":"Scichilone N, Callari A, Augugliaro G, Marchese M, Togias A, Bellia V. The impact of age on prevalence of positive skin prick tests and specific IgE tests. Respir Med. 2011;105(5):651\u20138.","journal-title":"Respir Med"},{"issue":"12","key":"397_CR32","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1586\/1744666X.2015.1087850","volume":"11","author":"S Battaglia","year":"2015","unstructured":"Battaglia S, Benfante A, Scichilone N. Asthma in the older adult: presentation, considerations and clinical management. Expert Rev Clin Immunol. 2015;11(12):1297\u2013308.","journal-title":"Expert Rev Clin Immunol."},{"issue":"11","key":"397_CR33","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1016\/j.rmed.2009.06.014","volume":"103","author":"G Brusselle","year":"2009","unstructured":"Brusselle G, Michils A, Louis R, Dupont L, Van de Maele B, Delobbe A, et al. \u201cReal-life\u201d effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study. Respir Med. 2009;103(11):1633\u201342. doi: 10.1016\/j.rmed.2009.06.014 .","journal-title":"Respir Med"},{"issue":"3","key":"397_CR34","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/02770900701247277","volume":"45","author":"RJ Maykut","year":"2008","unstructured":"Maykut RJ, Kianifard F, Geba GP. Response of older patients with age-mediated asthma to omalizumab: a pooled analysis. J Asthma. 2008;45(3):173\u201381. doi: 10.1080\/02770900701247277 .","journal-title":"J Asthma"},{"key":"397_CR35","doi-asserted-by":"crossref","unstructured":"Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;1:CD003559.","DOI":"10.1002\/14651858.CD003559.pub4"},{"issue":"4","key":"397_CR36","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.anai.2010.07.007","volume":"105","author":"S Korn","year":"2010","unstructured":"Korn S, Schumann C, Kropf C, Stoiber K, Thielen A, Taube C, et al. Effectiveness of omalizumab in patients 50\u00a0years and older with severe persistent allergic asthma. Ann Allergy Asthma Immunol. 2010;105(4):313\u20139. doi: 10.1016\/j.anai.2010.07.007 .","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"397_CR37","doi-asserted-by":"publisher","first-page":"346","DOI":"10.2500\/aap.2011.32.3467","volume":"32","author":"P Verma","year":"2011","unstructured":"Verma P, Randhawa I, Klaustermeyer WB. Clinical efficacy of omalizumab in an elderly veteran population with severe asthma. Allergy Asthma Proc. 2011;32(5):346\u201350. doi: 10.2500\/aap.2011.32.3467 .","journal-title":"Allergy Asthma Proc."},{"issue":"5","key":"397_CR38","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.rmr.2015.07.005","volume":"33","author":"P Romand","year":"2016","unstructured":"Romand P, Kelkel E, Saint-Raymond C, Glas N, Caillaud D, Devouassoux G. Severe uncontrolled asthma in patients over 75\u00a0years old: treatment with omalizumab. Rev Mal Respir. 2016;33(5):397\u2013400. doi: 10.1016\/j.rmr.2015.07.005 .","journal-title":"Rev Mal Respir"},{"key":"397_CR39","doi-asserted-by":"publisher","unstructured":"Della Torre F, Limonta A, Della Torre E, Marchi E. Efficacy and safety of omalizumab in older patients with asthma. Allergy Eur J Allergy Clin Immunol. 2012;67:236. doi: 10.1111\/all.12035 .","DOI":"10.1111\/all.12035"},{"key":"397_CR40","first-page":"A4247","volume":"191","author":"DM Caillaud","year":"2015","unstructured":"Caillaud DM, Glas N, Kelkel E, Romand P, Saint-Raymond C, Devouassoux G. Pfrench survey of omalizumab prescription by pulmonologists for elderly patients with severe asthma. Am J Respir Crit Care Med. 2015;191:A4247.","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"397_CR41","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.rmed.2013.04.017","volume":"107","author":"GJ Braunstahl","year":"2013","unstructured":"Braunstahl GJ, Chen CW, Maykut R, Georgiou P, Peachey G, Bruce J. The eXpeRience registry: the \u2018real-world\u2019 effectiveness of omalizumab in allergic asthma. Respir Med. 2013;107(8):1141\u201351. doi: 10.1016\/j.rmed.2013.04.017 .","journal-title":"Respir Med"},{"key":"397_CR42","doi-asserted-by":"publisher","unstructured":"Mepolizumab: 240563, anti-IL-5 monoclonal antibody\u2014GlaxoSmithKline, anti-interleukin-5 monoclonal antibody\u2014glaxoSmithKline, SB 240563. Drugs R D. 2008;9(2):125\u201330. doi: 10.2165\/00126839-200809020-00006 .","DOI":"10.2165\/00126839-200809020-00006"},{"issue":"18","key":"397_CR43","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1007\/s40265-015-0513-8","volume":"75","author":"GM Keating","year":"2015","unstructured":"Keating GM. Mepolizumab: first global approval. Drugs. 2015;75(18):2163\u20139. doi: 10.1007\/s40265-015-0513-8 .","journal-title":"Drugs."},{"key":"397_CR44","doi-asserted-by":"publisher","unstructured":"Powell C, Milan SJ, Dwan K, Bax L, Walters N. Mepolizumab versus placebo for asthma. Cochrane Database Syst Rev. 2015;7:CD010834. doi: 10.1002\/14651858.CD010834.pub2 .","DOI":"10.1002\/14651858.CD010834.pub2"},{"key":"397_CR45","doi-asserted-by":"publisher","unstructured":"Price DB, Rigazio A, Campbell JD, Bleecker ER, Corrigan CJ, Thomas M, et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med. 2015;3(11):849\u201358. doi: 10.1016\/s2213-2600(15)00367-7 .","DOI":"10.1016\/s2213-2600(15)00367-7"},{"issue":"71","key":"397_CR46","first-page":"305","volume":"13","author":"J Corren","year":"2012","unstructured":"Corren J. Inhibition of interleukin-5 for the treatment of eosinophilic diseases. Discov Med. 2012;13(71):305\u201312.","journal-title":"Discov Med."},{"issue":"10","key":"397_CR47","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1056\/NEJMoa0808991","volume":"360","author":"P Haldar","year":"2009","unstructured":"Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360(10):973\u201384. doi: 10.1056\/NEJMoa0808991 .","journal-title":"N Engl J Med."},{"issue":"13","key":"397_CR48","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","volume":"371","author":"HG Ortega","year":"2014","unstructured":"Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198\u2013207. doi: 10.1056\/NEJMoa1403290 .","journal-title":"N Engl J Med."},{"issue":"9842","key":"397_CR49","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/s0140-6736(12)60988-x","volume":"380","author":"ID Pavord","year":"2012","unstructured":"Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651\u20139. doi: 10.1016\/s0140-6736(12)60988-x .","journal-title":"Lancet"},{"key":"397_CR50","doi-asserted-by":"crossref","first-page":"A4177","DOI":"10.1164\/rccm.201501-0055ED","volume":"191","author":"H Ortega","year":"2015","unstructured":"Ortega H, Mayer B, Yancey S, Katial R. Response to treatment with mepolizumab in elderly patients. Am J Respir Crit Care Med. 2015;191:A4177.","journal-title":"Am J Respir Crit Care Med"},{"issue":"suppl 58","key":"397_CR51","first-page":"4673","volume":"44","author":"J Corren","year":"2014","unstructured":"Corren J, Weinstein S, Janka L, O\u2019Brien C, Zangrilli J. A randomized phase 3 study of reslizumab efficacy in relation to blood eosinophil levels in patients with moderate to severe asthma. Eur Respir J. 2014;44(suppl 58):4673.","journal-title":"Eur Respir J"},{"issue":"5","key":"397_CR52","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/s2213-2600(15)00042-9","volume":"3","author":"M Castro","year":"2015","unstructured":"Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355\u201366. doi: 10.1016\/s2213-2600(15)00042-9 .","journal-title":"Lancet Respir Med."},{"issue":"suppl 58","key":"397_CR53","first-page":"P299","volume":"44","author":"L Bjermer","year":"2014","unstructured":"Bjermer L, Lemiere C, Maspero J, Ciesielska M, O\u2019Brien C, Zangrilli J. A randomized phase 3 study of the efficacy and safety of reslizumab in subjects with asthma with elevated eosinophils. Eur Respir J. 2014;44(suppl 58):P299.","journal-title":"Eur Respir J"},{"key":"397_CR54","doi-asserted-by":"crossref","unstructured":"Bernstein DI, Mansfield L, Zangrilli J, Garin M. Efficacy of reslizumab in older patients (>65\u00a0years) with asthma and elevated blood eosinophils: results from a pooled analysis of two phase 3, placebo-controlled trials. J Allergy Clin Immunol. 2016;137(2):AB86.","DOI":"10.1016\/j.jaci.2015.12.410"},{"key":"397_CR55","doi-asserted-by":"publisher","unstructured":"Brusselle G, Germinaro M, Eid S, Zangrilli J. Reslizumab in patients with late-onset asthma with elevated blood eosinophils. Eur Respir J. 2015;46 (suppl 59). doi: 10.1183\/13993003.congress2015.OA287 .","DOI":"10.1183\/13993003.congress2015.OA287"},{"issue":"11","key":"397_CR56","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/s2213-2600(14)70201-2","volume":"2","author":"M Castro","year":"2014","unstructured":"Castro M, Wenzel SE, Bleecker ER, Pizzichini E, Kuna P, Busse WW, et al. Benralizumab, an anti-interleukin 5 receptor \u03b1 monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med. 2014;2(11):878\u201390. doi: 10.1016\/s2213-2600(14)70201-2 .","journal-title":"Lancet Respir Med."},{"issue":"5","key":"397_CR57","first-page":"527","volume":"11","author":"J Mitchell","year":"2010","unstructured":"Mitchell J, Dimov V, Townley RG. IL-13 and the IL-13 receptor as therapeutic targets for asthma and allergic disease. Curr Opin Invest Drugs. 2010;11(5):527\u201334.","journal-title":"Curr Opin Invest Drugs."},{"issue":"1","key":"397_CR58","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/mcp.0000000000000005","volume":"20","author":"AD Parulekar","year":"2014","unstructured":"Parulekar AD, Atik MA, Hanania NA. Periostin, a novel biomarker of TH2-driven asthma. Curr Opin Pulm Med. 2014;20(1):60\u20135. doi: 10.1097\/mcp.0000000000000005 .","journal-title":"Curr Opin Pulm Med."},{"key":"397_CR59","first-page":"A2330","volume":"187","author":"H Kabata","year":"2013","unstructured":"Kabata H, Matsusaka M, Fukunaga K, Suzuki Y, Miyata J, Tanaka K, et al. Relationship between serum periostin levels and severity\/phenotype of asthma. Am J Respir Crit Care Med. 2013;187:A2330.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"397_CR60","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1183\/13993003.01384-2015","volume":"47","author":"J Fingleton","year":"2016","unstructured":"Fingleton J, Braithwaite I, Travers J, Bowles D, Strik R, Siebers R, et al. Serum periostin in obstructive airways disease. Eur Respir J. 2016;47(5):1383\u201391.","journal-title":"Eur Respir J"},{"key":"397_CR61","doi-asserted-by":"publisher","unstructured":"Johansson MW, Evans MD, Crisafi GM, Holweg CT, Matthews JG, Jarjour NN. Serum periostin is associated with type 2 immunity in severe asthma. J Allergy Clin Immunol. 2016;137(6):1904\u20137 e2. doi: 10.1016\/j.jaci.2015.12.1346 .","DOI":"10.1016\/j.jaci.2015.12.1346"},{"issue":"suppl 55","key":"397_CR62","first-page":"3425","volume":"38","author":"E Piper","year":"2011","unstructured":"Piper E, Brightling C, Niven R, Oh C, Faggioni R, Poon K, et al. Phase 2 randomized, double-blind, placebo-controlled study of tralokinumab, an anti-IL-13 monoclonal antibody, in moderate to severe asthma. Eur Respir J. 2011;38(suppl 55):3425.","journal-title":"Eur Respir J"},{"issue":"9","key":"397_CR63","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/s2213-2600(15)00197-6","volume":"3","author":"CE Brightling","year":"2015","unstructured":"Brightling CE, Chanez P, Leigh R, O\u2019Byrne PM, Korn S, She D, et al. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med. 2015;3(9):692\u2013701. doi: 10.1016\/s2213-2600(15)00197-6 .","journal-title":"Lancet Respir Med."},{"issue":"8","key":"397_CR64","doi-asserted-by":"publisher","first-page":"723","DOI":"10.4155\/cli.15.37","volume":"5","author":"WW Busse","year":"2015","unstructured":"Busse WW, Wang M, Gibson J, Gottlow M, Braddock M, Colice G. TROPOS: designing a clinical trial to evaluate the oral corticosteroid-sparing effect of a biologic in severe asthma. Clin Invest. 2015;5(8):723\u201330. doi: 10.4155\/cli.15.37 .","journal-title":"Clin Invest."},{"key":"397_CR65","unstructured":"Roche. Investor Update. http:\/\/www.roche.com\/ . 2016. http:\/\/www.roche.com\/investors\/updates\/inv-update-2016-02-29.htm . Accessed 29 Apr 2016."},{"issue":"10039","key":"397_CR66","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","volume":"388","author":"S Wenzel","year":"2016","unstructured":"Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388(10039):31\u201344.","journal-title":"Lancet"},{"key":"397_CR67","doi-asserted-by":"crossref","unstructured":"Kew KM, Undela K, Kotortsi I, Ferrara G. Macrolides for chronic asthma. Cochrane Database Syst Rev. 2015;9:CD002997.","DOI":"10.1002\/14651858.CD002997.pub4"},{"issue":"8","key":"397_CR68","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMoa1104623","volume":"365","author":"RK Albert","year":"2011","unstructured":"Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA Jr, Criner GJ, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689\u201398.","journal-title":"N Engl J Med"},{"issue":"2","key":"397_CR69","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1164\/rccm.200707-1134OC","volume":"177","author":"JL Simpson","year":"2008","unstructured":"Simpson JL, Powell H, Boyle MJ, Scott RJ, Gibson PG. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med. 2008;177(2):148\u201355.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"397_CR70","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1136\/thoraxjnl-2012-202698","volume":"68","author":"GG Brusselle","year":"2013","unstructured":"Brusselle GG, Vanderstichele C, Jordens P, Deman R, Slabbynck H, Ringoet V, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax. 2013;68(4):322\u20139.","journal-title":"Thorax"},{"issue":"5","key":"397_CR71","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1183\/09031936.00093913","volume":"42","author":"EJ Cameron","year":"2013","unstructured":"Cameron EJ, Chaudhuri R, Mair F, McSharry C, Greenlaw N, Weir CJ, et al. Randomised controlled trial of azithromycin in smokers with asthma. Eur Respir J. 2013;42(5):1412\u20135.","journal-title":"Eur Respir J"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-016-0397-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-016-0397-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-016-0397-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T21:43:11Z","timestamp":1601070191000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-016-0397-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":71,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["397"],"URL":"https:\/\/doi.org\/10.1007\/s40266-016-0397-7","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9]]}}}